Machine Learning Classifiers on Breast Cancer Recurrences DOI Open Access
Vincent Peter C. Magboo, Ma. Sheila A. Magboo

Procedia Computer Science, Journal Year: 2021, Volume and Issue: 192, P. 2742 - 2752

Published: Jan. 1, 2021

Breast cancer remains to be a leading cause of cancer-related deaths among women. Mortality is mainly attributed metastasis and recurrence. Hence, early detection breast recurrence has become real-world medical problem. Using data mining approaches, we compared four popular machine learning models (Logistic Regression, Naïve Bayes, K-Nearest Neighbors, Support Vector Machines) on high-dimensional but very small dataset, the Wisconsin Prognostic Cancer Data Set for classifying recurrences different configurations: a) only scaling applied, b) with PCA, c) PCA oversampling minority class, d) selected features (i.e. choose one from each set that have high correlation other). Our results showed Logistic Regression provided best scores in almost all metrics (precision, recall, accuracy, f1 score (weighted), AUROC, AUPROC, Cohen Kappa statistic configurations, followed by Machines, then Neighbors. Naive Bayes performed poorly especially configuration, however, when retained many correlations other, Bayed performance improved. KNN improved its recall while SVM's accuracy been fairly constant configurations. Based this study, model can serve as potential predicting would enable clinicians propose treatment options based whether patient's correspond good or bad prognosis (recurrence). This indicates clinical utility methods post-surgical patients save lives.

Language: Английский

Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures DOI Creative Commons
Dharambir Kashyap, Deeksha Pal, Riya Sharma

et al.

BioMed Research International, Journal Year: 2022, Volume and Issue: 2022, P. 1 - 16

Published: April 18, 2022

Breast cancer is a global cause for concern owing to its high incidence around the world. The alarming increase in breast cases emphasizes management of disease at multiple levels. should start from beginning that includes stringent screening or registry effective diagnostic and treatment strategies. highly heterogeneous morphology as well molecular levels needs different therapeutic regimens based on subtype. patients with respective subtype have clinical outcome prognoses. heterogeneity advanced testing will help on-time diagnosis improved survival. Emerging fields such liquid biopsy artificial intelligence would under complexity decide regimen helps management. In this review, we discussed various risk factors technology available combat worst status areas need be focused better cancer.

Language: Английский

Citations

402
Targeting Breast Cancer Stem Cells DOI Creative Commons
Lu Zhang, Wen‐Ming Chen, Suling Liu

et al.

International Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 19(2), P. 552 - 570

Published: Jan. 1, 2023

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence have been recognized for many decades.Due to their strong capacity self-renewal differentiation, BCSCs are the major reasons poor clinical outcomes low therapeutic response.Several hypotheses on origin proposed, including critical gene mutations cells, dedifferentiation somatic cell plasticity remodeling by epithelial-mesenchymal transition (EMT) microenvironment.Moreover, microenvironment, cellular components cytokines, modulates resistance BCSCs.Small molecules, antibodies, chimeric antigen receptor (CAR)-T targeting developed, applications combination with conventional therapies undergoing trials.In this review, we focus features BCSCs, emphasize factors environment that regulate stemness discuss BCSC-targeting therapies.

Language: Английский

Citations

112
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead DOI Creative Commons
M. Joyce Nirmala, Uma Kizhuveetil, Athira Johnson

et al.

RSC Advances, Journal Year: 2023, Volume and Issue: 13(13), P. 8606 - 8629

Published: Jan. 1, 2023

Cancer is known as the most dangerous disease in world terms of mortality and lack effective treatment. Research on cancer treatment still active great social importance. Since 1930, chemotherapeutics have been used to treat cancer. However, such conventional treatments are associated with pain, side effects, a targeting. Nanomedicines an emerging alternative due their targeting, bioavailability, low toxicity. Nanoparticles target cells via passive mechanisms. FDA approval for Doxil®, several nano-therapeutics developed, few received use Along liposomes, solid lipid nanoparticles, polymeric nanoemulsions, even newer techniques involving extracellular vesicles (EVs) thermal nanomaterials now being researched implemented practice. This review highlights evolution current status therapy, focus clinical/pre-clinical nanomedicine studies. Insight also provided into prospects this regard.

Language: Английский

Citations

105
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence DOI Open Access
Beatrice Aramini, Valentina Masciale, Giulia Grisendi

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(4), P. 976 - 976

Published: Feb. 15, 2022

Emerging evidence suggests that a small subpopulation of cancer stem cells (CSCs) is responsible for initiation, progression, and metastasis cascade in tumors. CSCs share characteristics with normal cells, i.e., self-renewal differentiation potential, suggesting they can drive progression. Consequently, targeting to prevent tumor growth or regrowth might offer chance lead the fight against cancer. create their niche, specific area within tissue unique microenvironment sustains vital functions. Interactions between niches play critical role regulating CSCs' tumorigenesis. Differences observed frequency CSCs, due phenotypic plasticity many remain challenge therapeutics, since modulate transcriptional activities into more stem-like state protect themselves from destruction. This represents an essential step future therapeutic approaches. Regarding self-renewal, are modulated by same molecular pathways found such as Wnt/β-catenin signaling, Notch Hedgehog signaling. Another key characteristic resistance standard chemotherapy radiotherapy treatments, capacity rest quiescent state. review will analyze primary mechanisms involved CSC tumorigenesis, particular attention roles progression benign malignant diseases; examine perspectives on identification new markers better control well dissecting process.

Language: Английский

Citations

92
Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice DOI
Yudong Song, Luke F. Bugada, Ruiting Li

et al.

Science Translational Medicine, Journal Year: 2022, Volume and Issue: 14(643)

Published: May 4, 2022

Immunomodulators that remodel the tumor immunosuppressive microenvironment have been combined with anti–programmed death 1 (α-PD1) or ligand (α-PDL1) immunotherapy but shown limited success in clinical trials. However, therapeutic strategies to modulate of lymph nodes largely overlooked. Here, we designed an albumin nanoparticle, Nano-PI, containing immunomodulators PI3Kγ inhibitor (IPI-549) and paclitaxel (PTX). We treated two breast cancer mouse models Nano-PI combination α-PD1, which remodeled both tumors. This achieved long-term remission eliminated lung metastases. PTX IPI-549 enabled formation a stable nanoparticle enhanced repolarization M2 M1 macrophages. not only delivery tumors also improved drug accumulation macrophages these tissues. Immune cell profiling revealed α-PD1 immune by polarizing macrophages, increasing CD4 + CD8 T cells, B dendritic decreasing regulatory preventing exhaustion. Our data suggest modulates achieve mice metastatic cancer, represents promising candidate for future

Language: Английский

Citations

74
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer DOI Creative Commons
Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2023, Volume and Issue: 15

Published: Jan. 1, 2023

Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor 2 negative (HR+/HER2−) advanced breast cancer. New Adjuvant Trial [LEE011] (NATALEE) is trial evaluating the efficacy safety of adjuvant ribociclib plus endocrine therapy (ET) versus ET alone HR+/HER2− early nonmetastatic cancer (EBC). Methods/design: NATALEE multicenter, randomized, open-label, Phase III EBC. Eligible include women, regardless menopausal status, men aged ⩾18 years. Select stage IIA, IIB, or disease (per anatomic classification AJCC Cancer Staging Manual, 8th edition) an initial diagnosis ⩽18 months prior to randomization are eligible. Patients receiving standard (neo)adjuvant eligible if treatment was initiated ⩽12 before randomization. undergo 1:1 400 mg/day (3 weeks on/1 week off) +ET (letrozole 2.5 anastrozole 1 [investigator’s discretion] goserelin [men premenopausal women]) alone. duration 36 months; ⩾60 months. The primary end point invasive disease-free survival. Discussion: 36-month extended compared that other cyclin-dependent kinases 4 6 (CDK4/6) inhibitor trials intended maximize due longer CDK4/6 inhibition. Compared 600-mg/day dose used cancer, reduced may improve tolerability while maintaining efficacy. includes broadest population EBC any currently treatment. registration: ClinicalTrials.gov identifier: NCT03701334 ( https://clinicaltrials.gov/ct2/show/NCT03701334 )

Language: Английский

Citations

68
Cancer metastasis: Molecular mechanisms and clinical perspectives DOI
Sameer Ullah Khan,

Kaneez Fatima,

Fayaz Malik

et al.

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 250, P. 108522 - 108522

Published: Sept. 1, 2023

Language: Английский

Citations

61
Recent advancements in artificial intelligence for breast cancer: Image augmentation, segmentation, diagnosis, and prognosis approaches DOI
Jiadong Zhang, Jiaojiao Wu, Xiang Sean Zhou

et al.

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 96, P. 11 - 25

Published: Sept. 12, 2023

Language: Английский

Citations

48
In situ forming pH/ROS-responsive niche-like hydrogel for ultrasound-mediated multiple therapy in synergy with potentiating anti-tumor immunity DOI

Zideng Dai,

Qiuhong Zhang, Xiaohong Li

et al.

Materials Today, Journal Year: 2023, Volume and Issue: 65, P. 62 - 77

Published: April 6, 2023

Language: Английский

Citations

45
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance DOI Creative Commons
Jing Wang, Baizhou Li, Meng Luo

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: April 3, 2024

Abstract Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal (IDC). The challenge lies distinguishing between non-progressive and progressive DCIS, often resulting over- or under-treatment many cases. With increasing screen-detected these years, the nature of has aroused worldwide attention. A deeper understanding biological molecular journey DCIS-IDC transition is crucial for more effective clinical management. Here, we reviewed key signaling pathways cancer that may contribute initiation progression. We also explored features IDC, shedding light on progression through both inherent changes within tumor cells alterations microenvironment. addition, valuable research tools utilized studying including preclinical models newer advanced technologies such as single-cell sequencing, spatial transcriptomics artificial intelligence, have been systematically summarized. Further, thoroughly discussed advancements prognostic biomarkers managements, with aim facilitating personalized treatment strategies future. Research already yielded significant insights into carcinogenesis will continue pave way practical applications.

Language: Английский

Citations

27